The usefulness and limitations of the diabetic macaque model in evaluating long-term porcine islet xenograft survival

Xenotransplantation

Volumn 20, Issue 1, 2013, Pages 5-17

  Graham, Melanie L ^a   Schuurman, Henk Jan ^a  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

diabetes; glucose control; immunosuppression; islet xenotransplantation; nonhuman primates; pigs; transplant model limitations

Indexed keywords

IMMUNOSUPPRESSIVE AGENT; INSULIN;

ALLOTRANSPLANTATION; ARTICLE; CHRONIC DISEASE; DIABETES MELLITUS; GLYCEMIC CONTROL; GRAFT SURVIVAL; HYPERGLYCEMIA; MACACA; NONHUMAN; PANCREAS ISLET; PRIORITY JOURNAL; SWINE; WEIGHT GAIN; WEIGHT REDUCTION; XENOGRAFT; XENOTRANSPLANTATION;

ANIMALS; BLOOD GLUCOSE; DIABETES MELLITUS, EXPERIMENTAL; GRAFT SURVIVAL; HUMANS; IMMUNOSUPPRESSION; ISLETS OF LANGERHANS TRANSPLANTATION; MACACA; MODELS, ANIMAL; SUS SCROFA; TRANSPLANTATION, HETEROLOGOUS; WEIGHT LOSS;

EID: 84873468988     PISSN: 0908665X     EISSN: 13993089     Source Type: Journal    
DOI: 10.1111/xen.12012     Document Type: Article

References (52)

1. Schuurman H-J,. Xenotransplantation. Drug Discov Today Dis Models 2008; 5: 81-87.
2. Dufrane D, Gianello P,. Pig islet xenotransplantation into non-human primate model. Transplantation 2008; 86: 753-760.
3. Hering BJ, Walawalkar N,. Pig-to-nonhuman primate islet xenotransplantation. Transpl Immunol 2009; 21: 81-86.
4. Cooper DKC, Keogh AM, Brink J, et al., Report of the Xenotransplantation Advisory Committee of the International Society for Heart and Lung Transplantation: the present status of xenotransplantation and its potential role in the treatment of end-stage cardiac and pulmonary diseases. J Heart Lung Transplant 2000; 19: 1125-1165.
5. Pierson RN 3rd, Dorling A, Ayares D, et al., Current status of xenotransplantation and prospects for clinical application. Xenotransplantation 2009; 16: 263-280.
6. Hering BJ, Cooper DK, Cozzi E, et al., The International Xenotransplantation Association consensus statement on conditions for undertaking clinical trials of porcine islet products in type 1 diabetes-executive summary. Xenotransplantation 2009; 16: 196-202.
7. Cooper DK, Casu A,. The International Xenotransplantation Association consensus statement on conditions for undertaking clinical trials of porcine islet products in type 1 diabetes-chapter 4: pre-clinical efficacy and complication data required to justify a clinical trial. Xenotransplantation 2009; 16: 229-238.
8. Hering BJ, Wijkstrom M, Graham ML, et al., Prolonged diabetes reversal after intraportal xenotransplantation of wild-type porcine islets in immunosuppressed nonhuman primates. Nat Med 2006; 12: 301-303.
9. Cardona K, Korbutt GS, Milas Z, et al., Long-term survival of neonatal porcine islets in nonhuman primates by targeting costimulation pathways. Nat Med 2006; 12: 304-306.
10. Thompson P, Cardona K, Russell M, et al., CD40-specific costimulation blockade enhances neonatal porcine islet survival in nonhuman primates. Am J Transplant 2011; 11: 947-957.
11. Cardona K, Milas Z, Strobert E, et al., Engraftment of adult porcine islet xenografts in diabetic nonhuman primates through targeting of costimulation pathways. Am J Transplant 2007; 7: 2260-2268.
12. Thompson P, Badell IR, Lowe M, et al., Islet xenotransplantation using Gal-deficient neonatal donors improves engraftment and function. Am J Transplant 2011; 11: 2593-2602.
13. Van Der Windt DJ, Bottino R, Casu A, et al., Long-term controlled normoglycemia in diabetic non-human primates after transplantation with hCD46 transgenic porcine islets. Am J Transplant 2009; 9: 2716-2726.
14. Hecht G, Eventov-Friedman S, Rosen C, et al., Embryonic pig pancreatic tissue for the treatment of diabetes in a nonhuman primate model. Proc Natl Acad Sci USA 2009; 106: 8659-8664.
15. Dufrane D, Goebbels RM, Gianello P,. Alginate macroencapsulation of pig islets allows correction of streptozotocin-induced diabetes in primates up to 6 months without immunosuppression. Transplantation 2010; 90: 1054-1062.
16. Thompson P, Badell IR, Lowe M, et al., Alternative immunomodulatory strategies for xenotransplantation: CD40/154 pathway-sparing regimens promote xenograft survival. Am J Transplant 2012; 12: 1765-1775.
17. Rood PPM, Bottino R, Balamurugan AN, et al., Induction of diabetes in cynomolgus monkeys with high-dose streptozotocin: adverse effects and early responses. Pancreas 2006; 33: 287-292.
18. Graham ML, Mutch LA, Rieke EF, et al., Refining the high-dose streptozotocin-induced diabetic nonhuman primate model: an evaluation of risk factors and outcomes. Exp Biol Med 2011; 236: 1218-1230.
19. Graham ML, Mutch LA, Kittredge JA, et al., Management of adverse side-effects after chemotherapy in macaques as exemplified by streptozotocin: case studies and recommendation. Lab Anim 2012; 46: 178-192.
20. Graham ML, Rieke EF, Mutch LA, et al., Successful implementation of cooperative handling eliminates the need for restraint in a complex nonhuman primate disease model. J Med Primatol 2012; 41: 89-106.
21. Bansal-Pakala P, Pahuja A, Hennessey E, et al., Ex vivo expanded Treg therapy promotes long-term islet allograft survival in a non-human primate model. Am J Transplant 2011; 11 (Suppl. 2): 209.
22. Graham ML, Rieke EF, Dunning M, et al., A novel alternative placement site and technique for totally implantable vascular access ports in non-human primates. J Med Primatol 2009; 38: 204-212.
23. Graham ML, Mutch LA, Rieke EF, et al., Refinement of vascular access port placement in nonhuman primates: complication rates and outcomes. Comp Med 2010; 60: 479-485.
24. Graham ML, Mutch LA, Rieke EF, et al., Long-term hepatic vascular access in the nonhuman primate for recurrent portal vein infusion. J Invest Surg 2011; 24: 59-66.
25. Graham ML, Bellin MD, Papas KK, Hering BJ, Schuurman H-J,. Species incompatibilities in the pig-to-macaque islet xenotransplant model affect transplant outcome: a comparison with allotransplantation. Xenotransplantation 2011; 18: 328-342.
26. Wijkstrom M, Kirchhof N, Graham M, et al., Cyclosporine toxicity in immunosuppressed streptozotocin-diabetic nonhuman primates. Toxicology 2005; 207: 117-127.
27. Casu A, Bottino R, Balamurugan AN, et al., Metabolic aspects of pig-to-monkey (Macaca fascicularis) islet transplantation: implications for translation into clinical practice. Diabetologia 2008; 51: 120-129.
28. Wijkstrom M, Kenyon NS, Kirchhof N, et al., Islet allograft survival in nonhuman primates immunosuppressed with basiliximab, RAD, and FTY720. Transplantation 2004; 77: 827-835.
29. Kanmaz T, Fechner JJ Jr, Torrealba J, et al., Monotherapy with the novel human anti-CD154 monoclonal antibody ABI793 in rhesus monkey renal transplantation model. Transplantation 2004; 77: 914-920.
30. Takahashi M, Washio T, Suzuki N, et al., Characterization of gastrointestinal drug absorption in cynomolgus monkeys. Mol Pharm 2008; 5: 340-348.
31. US Department of Health and Human Services, Food and Drug Administration, Center For Drug Evaluation and Research. Guidance for Industry: Estimating the Maximum Safe Starting Dose in Initial Clinical Trials for Therapeutics in Adult Healthy Volunteers. Rockville MD, 2005. Available at: http:// www.fda.gov/downloads/Drugs/GuidanceCompliance- RegulatoryInformation/Guidances/ UCM078932.pdf [accessed on 3 July 2012].
32. Schuurman HJ, Slingerland W, Mennninger K, et al., Pharmacokinetics of cyclosporine in monkeys after oral and intramuscular administration: relation to efficacy in kidney allografting. Transpl Int 2001; 14: 320-328.
33. NEORAL® Soft Gelatin Capsules (cyclosporine capsules, USP) MODIFIED; NEORAL® Oral Solution (cyclosporine oral solution, USP) MODIFIED. Available at: http://www.pharma.us.novartis.com/product/pi/pdf/neoral.pdf [accessed on 3 July 2012].
34. PROGRAF tacrolimus capsules and injection. Available at: http://www.prograf.com/Professionals/Professionals.aspx?section= KidneyTransplantation [accessed on 3 July 2012].
35. RAPAMUNE (sirolimus) ORAL SOLUTION AND TABLETS. Available at: http://labeling.pfizer.com/showlabeling.aspx?id=139 [accessed on 3 July 2012].
36. CELLCEPT, mycophenolate mofetil. Available at: http://www.cellcept.com/ cellcept/ [accessed on 3 July 2012].
37. Montgomery SP, Mog SR, Xu H, et al., Efficacy and toxicity of a protocol using sirolimus, tacrolimus and daclizumab in a nonhuman primate renal allotransplant model. Am J Transplant 2002; 2: 381-385.
38. Graham M, Mutch L, Munson J, et al., Chronic immunosuppression with tacrolimus is associated with an increased risk of drug-induced diarrhea post islet xenotransplant in cynomolgus macaques. Xenotransplantation 2009; 16: 432.
39. Castaneda C,. Muscle wasting and protein metabolism. J Anim Sci 2002; 80 (Suppl. 2): E98-E105.
40. Haddad F, Zaldivar F, Cooper DM, et al., IL-6-induced skeletal muscle atrophy. J Appl Physiol 2005; 98: 911-917.
41. Dunn SE, Burns JL, Michel RN,. Calcineurin is required for skeletal muscle hypertrophy. J Biol Chem 1999; 274: 21908-21912.
42. Caso G, Mcnurlan MA,. Effect of insulin on whole body protein metabolism in children with type 1 diabetes. Curr Opin Clin Nutr Metab Care 2010; 13: 93-96.
43. Abraham BP, Sellin JH,. Drug-induced diarrhea. In:, Guandalini S, Vazari H, eds. Diarrhea, Clinical Gastroenterology, Chapter 23. New York: Springer Science plus Business Media, 2011; 23: 393- 423.
44. Dias VC, Madsen KL, Mulder KE, et al., Oral administration of rapamycin and cyclosporine differentially alter intestinal function in rabbits. Dig Dis Sci 1998; 43: 2227-2236.
45. Madsen KL, Yanchar NL, Sigalet DL, et al., FK506 increases permeability in rat intestine by inhibiting mitochondrial function. Gastroenterology 1995; 109: 107-114.
46. Yanchar NL, Riegel TM, Martin G, et al., Tacrolimus (FK506)-its effects on intestinal glucose transport. Transplantation 1996; 61: 630-634.
47. Gabe SM, Bjarnason I, Tolou-Ghamari Z, et al., The effect of tacrolimus (FK506) on intestinal barrier function and cellular energy production in humans. Gastroenterology 1998; 115: 67-74.
48. Baldwin MR, Arcasoy SM, Shah A, et al., Hypoalbuminemia and early mortality after lung transplantation: a cohort study. Am J Transplant 2012; 12: 1256-1267.
49. Molnar MZ, Kovesdy CP, Bunnapradist S, et al., Associations of pretransplant serum albumin with post-transplant outcomes in kidney transplant recipients. Am J Transplant 2011; 11: 1006-1015.
50. Goldwasser P, Feldman J,. Association of serum albumin and mortality risk. J Clin Epidemiol 1997; 50: 693-703.
51. Committee on Animal Nutrition, ad hoc Committee on Nonhuman Primate Nutrition, National Research Council. Nutrient Requirements of Nonhuman Primates, 2nd revised edn. Washington, DC: National Academies Press, 2003: 260.
52. Ryan EA, Lakey JR, Rajotte RV, et al., Clinical outcomes and insulin secretion after islet transplantation with the Edmonton protocol. Diabetes 2001; 50: 710-719.